
Devyser Diagnostics - Sticky business worthy of a premium

Redeye positively reviews the Thermo Fisher deal's potential and the company's US sales outlook. We raise our sales forecast on all time horizons and up our long-term EBIT assumptions, which increases our fair value range considerably. Devyser has finally started to get recognised for its strong sales and profitability prospects, but we argue that the share is far from fairly priced. The share is currently trading at a discount to peers despite ticking the boxes for a premium valuation, in our view.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Devyser Diagnostics - Sticky business worthy of a premium](#)